34 investment firms from six countries are already counted among over 130 participant companies already onboard, as well as pharma participants Merck, BMS, Shire, Teva, OSI and UCB.  Our aim for BioTrinity 2010 is to again increase participation by a further 25% to 600-650 delegates over April 12-14 2010.  The current rate of registration is about 2-fold higher than the previous year, strongly suggesting an even higher turnout in 2010 compared to 2009!

Here is a list of companies confirmed as participating


  • Abingworth (Sponsor)
  • AbD Serotec
  • Advent Ventures
  • Aescap Venture Management BV (Netherlands)
  • Albion Ventures
  • Almac
  • Alta Partners (US)
  • Atlas Venture
  • Beringea
  • BigDNA (Scotland)
  • Bioceramic Therapeutics
  • BioFocus DPI
  • BioGeneration Ventures (Netherlands)
  • BioPark
  • BioVex
  • Bristol Myers Squib
  • CellCentric
  • CellVax (France)
  • Charles River Laboratories
  • Communication Strategy Group, Inc. (US)
  • Covance Laboratories
  • Cyprotex
  • Domainex
  • De Facto Communications (Media Agent)
  • Drug Discovery Today (Media)
  • EBD Group
  • ECI Partners
  • Edmond de Rothschild Investment Partners (France)
  • ELGA Process Water
  • Entrepreneurs Fund
  • Epistem
  • Eviva Pharma
  • Evolution Securities
  • Evotec
  • Fisher Scientific
  • Focus (Bronze Sponsor)
  • Forbion Capital Partners (Netherlands)
  • Forresters
  • Frank B. Dehn & Co
  • Fry Heath Spence (Silver Sponsor)
  • Gen-Probe
  • George James
  • Giles Insurance Brokers Limited
  • GIMV (Belgium)
  • Glide Pharma
  • GlycoMar (Scotland)
  • G-Nostics
  • Golden Triangle Partnership
  • High Force Research
  • Hypha Discovery
  • Inhibox
  • Interea International
  • Intertek ASG
  • IP Group
  • IPSO Ventures
  • IQ Capital
  • JA Kemp & Co
  • JamesCowper (Bronze Sponsor)
  • Karus Therapeutics
  • KBC Peel Hunt
  • Kurma BioFund (France)
  • LCG Bioscience
  • London Genetics
  • LTN
  • Manches (Bronze sponsor)
  • McEwen Labs
  • MedImmune Ventures (USA)
  • Merck
  • Mewburn Ellis LLP
  • Morrison & Foerster (UK) LLP
  • M-Scan
  • MVM Life Science Partners
  • Novo A/S
    OrganOx
  • OBN
  • Orthox
  • OSI Pharmaceuticals (Platinum Sponsor)
  • Oxagen
  • Oxford Brookes University School of Life Sciences
  • Oxford Capital Partners
  • Oxford Contrast Molecular Diagnostics
  • Oxford Immunotec
  • Oxford Nanopore Technologies
  • Oxford Science Park
  • Parexel International
  • Partnering Excellence
  • Patheon UK Limited
  • Pharma Business Solutions
  • Pharma Clinical AG (Switzerland)
  • Pharmalicensing (Media)
  • PharmaNet (Bronze sponsor)
  • Pharm-Olam International
  • Pharmatic
  • PharmaTV
  • PharmaVentures
  • PiR Interims
  • PULSE Scientific
  • Quest for Growth (Belgium)
  • QuickSTAT
  • Ranbaxy Labs (India) [part of Daiichi Sankyo]
  • Rainbow Seed Fund
  • Reed Scientific
  • Riverbank IT Management
  • Rosetta Capital
  • Saturn Biosciences
  • Seroba Kernel (Ireland)
  • Shire Pharma (Silver Sponsor)
  • Silicos NV
  • Simbec Research
  • Solid Form Solutions Ltd
  • SPARK Venture Management Holdings
  • SRG
  • SR One
  • Summit plc
  • Synairgen Research
  • Syntagon (Sweden)
  • Syntaxin
  • Takeda Research Investment (US)
  • Technikos
  • Technomark Life Sciences (Platinum Sponsor)
  • Teva Pharmaceutical Industries (Silver Sponsor)
  • Thames Valley Innovation and Growth Team
  • TransPerfect Trial Interactive
  • Ubichem
  • UCB
  • University of Southampton
  • Vantia
  • Versant EuroVentures (Switzerland)
  • Vivacta
  • VWR International
  • World Courier (Bronze Sponsor)
  • Xention Limited




BioTrinity 2013 highlights
877 delegates from 28 countries
520 companies
168 speakers
86 company presentations
1679 scheduled one-to-one meetings
97 investors from 11 countries
66 exhibitors
32 global pharma/corporate venture